Related Experiment Video
Updated: Feb 5, 2026

Engineering and Evolution of Synthetic Adeno-Associated Virus AAV Gene Therapy Vectors via DNA Family Shuffling
Published on: April 2, 2012
Combination gene therapy with AAV based RPE65 and survivin vectors sustains phenotypic rescue in neural retina of
Vijayata Singh1, Shamshul Huda1, G Narendra Kumar1
1Department of Biological Sciences and Bioengineering & Mehta Family Center for Engineering in Medicine & Gangwal School of Medical Sciences and Technology, Indian Institute of Technology, Kanpur, Uttar Pradesh, 208 016, India.
Abstract:
Leber congenital amaurosis type 2 (LCA2) is an inherited retinal disorder, with severe vision impairment in children, progressing to complete blindness in the later stages of life. The current approved treatment involves Adeno-associated virus (AAV) vector serotype 2-based subretinal delivery of human RPE65 gene. However, long-term follow-up have reported gradual loss of phenotypic response. To overcome this, we have pursued strategies aimed at improving the transduction efficacy of the vector, optimizing the transgene for enhanced protein expression and co-delivering the therapeutic vector along with the anti-apoptotic factor, Survivin /baculoviral IAP repeat containing 5 (BIRC5) gene in the neural retina. We tested the efficacy of modified RPE65 transgene (Kozak/ codon optimized [CodOpt]) carried by an improved AAV2 vector (AAV2K665Q) against RPE65 wild type (WT) and observed that vector carrying CodOptRPE65 performed 1.8-fold better in vitro. Subsequently, the codon optimized RPE65 transgene containing vector was evaluated in a pre-clinical mouse model of LCA2 (rd12) with co-delivery of Survivin in an AAV5 vector. Animals were monitored for up to 6 months, and electroretinography revealed improved A- and B-wave response of 2.57- fold and 1.76-fold, respectively in combination treated eyes (CodOptRPE65 + Survivin) as compared to mock group. Co-delivery of CodOptRPE65 + Survivin did not significantly enhance retinal function by ERG when compared to AAV2K665Q-CMV-codon-optimized RPE65 alone. However, immunohistochemistry revealed that expression of apoptotic marker Bax is significantly reduced and anti-apoptotic marker Bcl2 significantly increased in animals receiving the combination therapy. A TUNEL assay further confirmed the decrease in apoptosis in the combination treatment group. These findings suggest that incorporating anti-apoptotic factors may strengthen the phenotypic rescue and control degeneration of the neural retina in LCA2 patients, offering a promising avenue for future clinical implementation.
More Related Videos
09:20Isolation of Next-Generation Gene Therapy Vectors through Engineering, Barcoding, and Screening of Adeno-Associated Virus AAV Capsid Variants
Published on: October 18, 2022
05:09Lumbar Intrathecal Injection of Gene Therapy Vectors for Central Nervous System Targeting in Mice and Rats
Published on: May 16, 2025
Related Concept Videos
Gene Therapy
Sustainable Development
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The Retina
Design Example: Sustainability in Concrete Building
There are multiple approaches to achieve sustainability in a commercial concrete building. For instance, construct a concrete parking area under the building, utilizing pervious concrete paver blocks in open areas to facilitate rainwater collection through an underground...
Vectors